Fluoxetine
|
|
Fluoxetine Eigenschaften
- Schmelzpunkt:
- 158 °C
- Siedepunkt:
- 395.1±42.0 °C(Predicted)
- Dichte
- 1.159±0.06 g/cm3(Predicted)
- storage temp.
- 2-8°C(protect from light)
- L?slichkeit
- 12.5mg/mL in DMSO, 16mg/mL in DMF, 12.5mg/mL in Ethanol
- pka
- 10.05±0.10(Predicted)
- Aggregatzustand
- Liquid
- Farbe
- Colorless to light yellow
- InChI
- InChI=1S/C17H18F3NO/c1-21-12-11-16(13-5-3-2-4-6-13)22-15-9-7-14(8-10-15)17(18,19)20/h2-10,16,21H,11-12H2,1H3
- InChIKey
- RTHCYVBBDHJXIQ-UHFFFAOYSA-N
- SMILES
- C(CCNC)(OC1C=CC(C(F)(F)F)=CC=1)C1=CC=CC=C1
- CAS Datenbank
- 54910-89-3(CAS DataBase Reference)
- NIST chemische Informationen
- Fluoxetine(54910-89-3)
- EPA chemische Informationen
- Benzenepropanamine, N-methyl-?-[4-(trifluoromethyl)phenoxy]- (54910-89-3)
Sicherheit
- Risiko- und Sicherheitserkl?rung
- Gefahreninformationscode (GHS)
Bildanzeige (GHS) |
![]() |
|||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Alarmwort | Warnung | |||||||||||||||||||||||||||||||||||
Gefahrenhinweise |
|
|||||||||||||||||||||||||||||||||||
Sicherheit |
|
Fluoxetine Chemische Eigenschaften,Einsatz,Produktion Methoden
Verwenden
antibacterialBiologische Funktion
Fluoxetine (Prozac) is given in the morning because of its potential for being activating and causing insomnia. Food does not affect its systemic bioavailability and may actually lessen the nausea reported by some patients. Fluoxetine is highly bound to serum proteins and may interact with other highly protein bound drugs. It is demethylated in the liver to form an active metabolite, norfluoxetine. Inactive metabolites are excreted by the kidney.Doses must be reduced in patients with liver disease.The slow elimination of fluoxetine and norfluoxetine lead to special clinical concerns when adjusting doses and discontinuing this medication. Steady state is not reached until 4 to 6 weeks, and similarly, complete elimination takes 4 to 6 weeks after discontinuation of the medication. A 4- to 6-week waiting period should be permitted before starting a medication with potential for an interaction with fluoxetine, such as a monoamine oxidase inhibitor (MAOI). Additionally, fluoxetine is a potent inhibitor of cytochrome P450 2D6 and can significantly elevate levels of drugs metabolized by this route. Thus, coadministration of drugs with a narrow therapeutic index, such as TCAs and type 1C antiarrhythmics, including flecainide and propafenone, are a particular concern.
Allgemeine Beschreibung
In fluoxetine (Prozac), protonated in vivo, the protonatedamino group can H-bond to the ether oxygen electrons, whichcan generate the β-arylamino–like group, with the other arylserving as the characteristic “extra” aryl. The S-isomer ismuch more selective for SERT than for NET. The majormetabolite is the N-demethyl compound, which is as potent asthe parent and more selective (SERT versus NET).Therapy for 2 or more weeks is required for the antidepressanteffect. Somatodendritic 5-HT1A autoreceptor desensitizationwith chronic exposure to high levels of 5-HT isthe accepted explanation for the delayed effect for this andother serotonin reuptake inhibitors.
Mechanism of action
Fluoxetine is a potent and selective inhibitor of 5-HT reuptake, but not of NE or dopamine uptake in the CNS. Its mechanism of action is common to the SSRIs. Fluoxetine does not interact directly with postsynaptic 5-HT receptors and has weak affinity for the other neuroreceptors. Both enantiomers of fluoxetine display similar affinities for human SERT. The NE:5-HT selectivity ratio, however, indicates that the S-enantiomer is approximately 100 times more selective for SERT inhibition than the R-enantiomer. The R-(+)-stereoisomer is approximately eight times more potent an inhibitor of SERT together with a longer duration of action than the S-(–)-isomer. However, the S-(–)-norfluoxetine metabolite is seven times more potent as an inhibitor of the 5-HT transporter than the R-(+)-metabolite, with a selectivity ratio approximately equivalent to that of S-fluoxetine.Pharmakokinetik
The pharmacokinetics of fluoxetine fit the general characteristics of the SSRIs. Of particular importance is its long half-life contributing to its nonlinear pharmacokinetics. In vitro studies show that fluoxetine and norfluoxetine are potent inhibitors of CYP2D6 and CYP3A4 and less potent inhibitors of CYP2C9, CYP2C19 and CYP1A2. Fluoxetine is metabolized primarily by CYP2D6 N-demethylation to its active metabolite norfluoxetine and, to a lesser extent, O-dealkylation to form the inactive metabolite p-trifluoromethylphenol. Following oral administration, fluoxetine and its metabolites are excreted principally in urine, with approximately 73% as unidentified metabolites, 10% as norfluoxetine, 10% as norfluoxetine glucuronide, 5% as fluoxetine N-glucuronide, and 2% as unmetabolized drug.Both R- and S-Norfluoxetine were less potent than the corresponding enantiomers of fluoxetine as inhibitors of NE uptake. Inhibition of 5-HT uptake in cerebral cortex persisted for more than 24 hours after administration of S-norfluoxetine similarly to fluoxetine. Thus, S-norfluoxetine is the active N-demethylated metabolite responsible for the persistently potent and selective inhibition of 5-HT uptake in vivo.
The pharmacokinetics of fluoxetine in healthy geriatric individuals do not differ substantially from those in younger adults. Because of its relatively long half-life and nonlinear pharmacokinetics, the possibility of altered pharmacokinetics in geriatric individuals could exist, particularly those with systemic disease and/or in those receiving multiple medications concurrently. The elimination half-lives of fluoxetine and norfluoxetine do not appear to be altered substantially in patients with renal or hepatic impairment.
Pharmakologie
Fluoxetine is a phenylpropylamine that inhibits the neuronal reuptake of serotonin, which presumably has a direct relationship on antidepressant activity. This compound has either no effect or a small effect on the neuronal reuptake of norepinephrine and dopamine. In addition, it does not bind to cholinergic, histaminergic, or α-adrenergic receptors, which is believed to be the cause of tricyclic antidepressant side effects.Clinical Use
Fluoxetine is a 3-phenoxy-3-phenylpropylamine that exhibits selectivity and high affinity for human SERT and low affinity for NET. It is marketed as a racemic mixture of R- and S-fluoxetine. Its selectivity for SERT inhibition depends on the position of the substituent in the phenoxy ring.Arzneimittelwechselwirkung
Fluoxetine and its norfluoxetine metabolite, like many other drugs metabolized by CYP2D6, inhibit the activity of CYP2D6 and, potentially, may increase plasma concentrations of concurrently administered drugs that also are metabolized by this enzyme. Fluoxetine may make normal CYP2D6 metabolizers resemble poor metabolizers. Fluoxetine can inhibit its own CYP2D6 metabolism, resulting in higher-than-expected plasma concentrations during upward dose adjustments. Therefore, switching from fluoxetine to another SSRI or other serotonergic antidepressant requires a washout period of at least 5 weeks or a lowerthan-recommended initial dose with monitoring for adverse events.Fluoxetine is highly protein bound and may affect the free plasma concentration and, thus, the pharmacological effect of other highly protein-bound drugs (e.g., warfarin sodium).
Fluoxetine Upstream-Materialien And Downstream Produkte
Upstream-Materialien
α,α,α-Trifluortoluol
Dimethylacetamide (DMAC)
Kaliumiodid
Methylamin, gasf?rmig
Paraformaldehyde
Methyl[3-phenyl-3-[4-(trifluormethyl)phenoxy]propyl]ammoniumchlorid
Acetophenon
Diboran (6)
α-[2-(Methylamino)ethyl]benzylalkohol
Kaliumtetrahydroborat
Secondary amine
Propiophenon
N,N-Dimethylacetamid
Thionyldichlorid
4-Fluorphenol
Bromcyan
4-Chlor-α,α,α-trifluortoluol
Schwefelsure
Natriumhydroxid
Ethandiol
Hydrogenchlorid
α,α,α-Trifluor-p-kresol
Kaliumhydroxid
Downstream Produkte
Fluoxetine Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.
Global( 220)Lieferanten
Firmenname | Telefon | Land | Produktkatalog | Edge Rate | |
---|---|---|---|---|---|
Hebei Zhanyao Biotechnology Co. Ltd | 15369953316 +8615369953316 |
admin@zhanyaobio.com | China | 2123 | 58 |
Shaanxi Dideu Medichem Co. Ltd | +86-29-81148696 +86-15536356810 |
1022@dideu.com | China | 3889 | 58 |
Hebei Yanxi Chemical Co., Ltd. | +8618531123677 |
faithe@yan-xi.com | China | 5853 | 58 |
Hangzhou ICH Biofarm Co., Ltd | +86-0571-28186870; +undefined8613073685410 |
sales@ichemie.com | China | 1014 | 58 |
Hangzhou Hyper Chemicals Limited | +86-0086-57187702781 +8613675893055 |
info@hyper-chem.com | China | 295 | 58 |
Shaanxi TNJONE Pharmaceutical Co., Ltd | +86-17396673057 |
linda@tnjone.com | China | 1143 | 58 |
Beijing Cooperate Pharmaceutical Co.,Ltd | 010-60279497 |
sales01@cooperate-pharm.com | CHINA | 1803 | 55 |
Henan Tianfu Chemical Co.,Ltd. | +86-0371-55170693 +86-19937530512 |
info@tianfuchem.com | China | 21622 | 55 |
Shanxi Naipu Import and Export Co.,Ltd | +86-13734021967 +8613734021967 |
kaia@neputrading.com | China | 1001 | 58 |
Hubei Jusheng Technology Co.,Ltd. | 18871490254 |
linda@hubeijusheng.com | CHINA | 28172 | 58 |
54910-89-3()Verwandte Suche:
Thiophanat-methyl
Flupirtin
Methylacetat
Methyl-4-hydroxybenzoat
Methylthenoat
Bensulfuron methyl
Kresoxim-methyl
Methylacrylat
Methyl
Brommethan
FLUOXETINE HYDROCHLORIDE
Parathion-methyl (ISO)
(-)-Methyl(α-methylphenethyl)amin
Methyl[3-phenyl-3-[4-(trifluormethyl)phenoxy]propyl]ammoniumchlorid
Halothan
- (+/-)-n-methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine
- METHYL-[3-PHENYL-3-(4-TRIFLUOROMETHYLPHENOXY)PROPYL]AMINE
- AURORA KA-7692
- FLUOXETINE
- (+-)-benzenepropanamin
- (+)or(-)-n-methyl-3-phenyl-3-(alpha,alpha,alpha-trifluoro-p-tolyl)oxy)prop
- (+)or(-)-n-methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine
- dl-3-(p-trifluoromethylphenoxy)-n-methyl-3-phenylpropylamine
- fluoxetina
- Fluoxetine###FLUOXETINE HYDROCHLORIDE
- n-methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine
- n-methyl-gamma-(4-(trifluoromethyl)phenoxy)-(+-)-benzenepropamin
- Fluctin
- Fluoxeren
- Foxetin
- Reneuron
- 3-(p-Trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine
- Fluval
- N-Methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propylamine
- (3S)-N-Methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propane-1-amine
- (S)-3-Phenyl-3-[4-(trifluoromethyl)phenoxy]-N-methyl-1-propanamine
- (S)-N-Methyl-γ-[4-(trifluoromethyl)phenoxy]benzenepropan-1-amine
- (S)-N-Methyl-γ-[4-(trifluoromethyl)phenoxy]benzenepropanamine
- (3R)-N-Methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propane-1-amine
- (R)-3-Phenyl-3-[4-(trifluoromethyl)phenoxy]-N-methyl-1-propanamine
- (R)-N-Methyl-γ-[4-(trifluoromethyl)phenoxy]benzenepropan-1-amine
- (R)-N-Methyl-γ-[4-(trifluoromethyl)phenoxy]benzenepropanamine
- Methyl[(3S)-3-phenyl-3-[4-(trifluoroMethyl)phenoxy]propyl]aMine
- Duloxetine hydrochoride
- N-Methyl-3-Phenyl-3-[(A-Trifluoro-P-Tolyl)Oxy]Propylamine
- Fluoxetine (base and/or unspecified salts)
- N-methyl-3-[4-(trifluoromethyl)phenoxy]-3-(3-tritiophenyl)propan-1-amine
- Benzenepropanamine, N-methyl-γ-[4-(trifluoromethyl)phenoxy]-
- Fluoxetine USP/EP/BP
- Fluoxetine (1.0 mg/mL in Methanol)
- Adofen
- N-Methyl-3-phenyl-3-(4-(trifluoroMethyl)phenoxy)propan-1-aMine
- LY-110140 (free base)
- Fluoxetine in methanol
- Fluoxetine, 10 mM in DMSO
- Fluoxetine (LY-110140)
- 54910-89-3
- C17H18F3NO
- C17H18NOF3
- CEFTIN
- API